Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 1,194

What We Owe The Future is available now — you can get it wherever you get your (audio)books or here: https://www.amazon.com/What-Owe-Future-William-MacAskill/dp/…atfound-20
This video was sponsored by the author, Will MacAskill. Thanks a lot for the support.

Sources & further reading:
https://sites.google.com/view/sources-civilization-collapse/

At its height, the Roman Empire was home to about 30% of the world’s population, and in many ways the pinnacle of human advancement. Rome became the first city in history to reach one million inhabitants and was a center of technological, legal, and economic progress. An empire impossible to topple, stable and rich and powerful.
Until it wasn’t anymore. First slowly then suddenly, the most powerful civilization on earth collapsed. If this is how it has been over the ages, what about us today? Will we lose our industrial technology, and with that our greatest achievements, from one dollar pizza to smartphones or laser eye surgery? Will all this go away too?

OUR CHANNELS
▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀
German: https://kgs.link/youtubeDE
Spanish: https://kgs.link/youtubeES
French: https://kgs.link/youtubeFR
Portuguese: https://kgs.link/youtubePT
Arabic: https://kgs.link/youtubeAR
Hindi: https://kgs.link/youtubeHI
Japanese: https://kgs.link/youtubeJA
Korean: https://kgs.link/youtubeKO

HOW CAN YOU SUPPORT US?
▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀▀
This is how we make our living and it would be a pleasure if you support us!

Get Products designed with ❤ https://shop-us.kurzgesagt.org.

Continue reading “Is Civilization on the Brink of Collapse?” | >

Did they unlock one of the vital keys to stop aging?

According to a recent National Eye Institute (NEI) study in mice, loss of the protein pigment epithelium-derived factor (PEDF), which protects retinal support cells, may promote age-related changes in the retina.

Age-related retinal diseases, such as age-related macular degeneration (AMD), can cause blindness since the retina is the light-sensitive tissue at the back of the eye. The new information could help develop medicines to stop AMD and other aging conditions of the retina. The research was published in the International Journal of Molecular Sciences. NEI is part of the National Institutes of Health.

“People have called PEDF the ‘youth’ protein because it is abundant in young retinas, but it declines during aging,” said Patricia Becerra, Ph.D., chief of NEI’s Section of Protein Structure and Function and senior author of the study. “This study showed for the first time that just removing PEDF leads to a host of gene changes that mimic aging in the retina.”

Read more | >

Dr Vittorio Sabastiano explains the possibilities on resetting the age of any cell type in the near future in this clip.

Dr. Vittorio Sebastiano is an Assistant Professor in the Department of Obstetrics and Gynecology at Stanford School of Medicine. His lab has established a new technology named ERA (Epigenetic Reprogramming of Aging), which repurposes the conceptual idea of reprogramming, with the goal to promote epigenetic rejuvenation of adult cells leaving their identity untouched. This new technology was patented and is being implemented by Turn Biotechnologies, of which Dr. Sebastiano is co-founder and Chair of the Scientific Advisory Board.

In 2009, Dr. Sebastiano completed a postdoctoral fellowship at the laboratory of Dr. Marius Wernig at Stanford University, where he implemented the newly discovered iPSC technology and was among the first to demonstrate that iPSCs can be efficiently derived, genetically modified, and implemented for cell therapy in genetic diseases (Sebastiano et al., 2014, Science Translational Medicine).
Dr. Sebastiano completed his undergraduate and graduate studies at the University of Pavia, Italy, where he studied murine germ cells and preimplantation development and where he pioneered cellular reprogramming by Somatic Cell Nuclear Transfer. He joined the Max Planck Institute for Molecular Biomedicine as a postdoctoral fellow under the mentorship of Dr. Hans Robert Schöler, where he continued his research on cellular reprograming, germ cells biology, and embryonic development.

DISCLAIMER: Please note that none of the information in this video constitutes health advice or should be substituted in lieu of professional guidance. The video content is purely for informational purposes.

#ForeverYoung #ReverseAging #reprogramming #VittorioSabastiano #Stanford #DavidSinclair #NMN sirtuin #NadBooster #Exercise #NAD #BeingHungry #NMN #Rejuvenate #Reprogramming #Mitochondria #ALA #Metformin #PQQ #CoQ10 #Carnitine #Antioxidant #LookYounger #NMN #Resveratrol #Quercetin #Fisetin #senolytics #OliveOil #Sirtuin #HIIT #aging #Lifespan #NMN #NR #Spermidine #Metformin #Berberine #ReverseAging #Epigenetic #OleicAcid #NMN #NAD #Sirtuins #Fasting #Longevity #RestoreYouth #Reprogramming #DavidSinclair #DrSinclairLab #Healthspan #Younger #antiaging #DrSinclair #NAD #longevity #Bioscience #Epigenome

Read more | >

An experimental combination of two drugs halts the progression of small cell lung cancer, the deadliest form of lung cancer, according to a study in mice from researchers at Washington University School of Medicine in St. Louis, Grenoble Alpes University in Grenoble, France, and The University of Texas MD Anderson Cancer Center in Houston.

One of the drugs, cyclophosphamide, is an outdated chemotherapy drug once used to treat small cell lung cancer. It was displaced in favor of platinum-based drugs in the 1980s. Both kinds of drugs work at first but falter after a few months as the cancer develops resistance. Platinum-based drugs became the standard of care mainly because they cause lesser side effects, but they have not substantially improved prognosis. Today, the typical patient survives less than a year and a half after diagnosis.

In this study, however, researchers showed that small cell lung cancer cells resist cyclophosphamide by activating a specific repair process, and demonstrated that throwing a wrench into the repair process makes the drug much more effective, at least in mice. The findings, available online in Cancer Discovery, suggest a pathway to better therapies for one of the least treatable forms of cancer.

Read more | >

The Dunedin Pace of Aging Algorithm (PACE) was created by researchers from Duke, and the University of Otago over the course of 50 years of longitudinal research. It offers a revolutionary way to track aging which looks at an individual’s current rate of aging, and now TruDiagnostic has announced it is offering this powerful, third-generation clock to the public at an affordable price through TruAge PACE.

Longevity. Technology: Biologically, aging is the process of human cells slowly losing function over time; this process can be tracked by examining molecular markers called methylation and using advanced algorithms to sort those markers and calculate a person’s biological age – how old they are biologically rather than they number of birthdays they have clocked up.

The ability to track aging is dependent on the ability of the algorithms themselves. Until recently, most algorithms were trained on chronological age, and this meant they had poor responsiveness to interventions that are known to impact the biological course of aging. PACE gives individuals t he ability to detect rapid aging at an early age.

Read more | >

In a recent publication in the journal Advanced Materials, a team of physicists and chemists from TU Dresden presents an organic thin-film sensor that describes a completely new way of identifying the wavelength of light and achieves a spectral resolution below one nanometer. As integrated components, the thin-film sensors could eliminate the need for external spectrometers in the future. A patent application has already been filed for the novel technology.

Spectroscopy comprises a group of experimental methods that decompose radiation according to a specific property, such as wavelength or mass. It is considered one of the most important analytical methods in research and industry. Spectrometers can determine colors (wavelengths) of light sources and are used as sensors in various applications, such as medicine, engineering, food industry and many more. Commercially available instruments are usually relatively large and very expensive. They are mostly based on the principle of the prism or grating: light is refracted and the wavelength is assigned according to the angle of refraction.

At the Institute for Applied Physics (IAP) and the Dresden Integrated Center for Applied Physics and Photonic Materials (IAPP) of the TU Dresden, such sensor components based on organic semiconductors have been researched for years. With the spin-offs Senorics and PRUUVE, two technologies have already been developed towards market maturity. Now, researchers at the IAP and IAPP, in cooperation with the Institute of Physical Chemistry, have developed a thin-film sensor that describes a completely new way of identifying the and, due to its small size and cost, has clear advantages over commercially available spectrometers.

Read more | >

In a new study published in Science, researchers have used single-nucleus sequencing (sNuc-Seq) to characterize the cell populations of the axolotl forebrain, an aquatic salamander that can regenerate brain tissue post-injury.

Axolotls – a translational model

The brain is a complex organ, comprising billions of cells and neuronal connections that form intricate networks. Understanding which cells are actively engaged in neurological processes – and which genes underpin this activity – can help us to decipher this complexity. It is only recently that advances in single-cell sequencing have made such research possible, providing insights on the molecular signatures of thousands of individual cells.

Read more | >

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This combined stem cell and gene therapy can potentially protect diseased motor neurons in the spinal cord of patients with amyotrophic lateral sclerosis, a fatal neurological disorder known as ALS or Lou Gehrig’s disease.

In the first trial of its kind, the Cedars-Sinai team showed that delivery of this combined treatment is safe in humans. The findings were reported today in the peer-reviewed journal Nature Medicine.

“Using stem cells is a powerful way to deliver important proteins to the brain or spinal cord that can’t otherwise get through the ,” said senior and corresponding author Clive Svendsen, Ph.D., professor of Biomedical Sciences and Medicine and executive director of the Cedars-Sinai Board of Governors Regenerative Medicine Institute. “We were able to show that the engineered stem cell product can be safely transplanted in the human spinal cord. And after a one-time treatment, these cells can survive and produce an important protein for over three years that is known to protect that die in ALS.”

Read more | >